Sun Pharma’s New Study on Tildrakizumab: A Potential Game Changer for Genital Psoriasis

Sun Pharmaceutical Industries Limited ((IN:SUNPHARMA)) announced an update on their ongoing clinical study.

Study Overview: Sun Pharmaceutical Industries Limited is conducting a Phase 3 study titled A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. The study aims to assess the effectiveness and safety of tildrakizumab, a promising treatment for individuals suffering from moderate to severe genital psoriasis, a condition that significantly impacts quality of life.

Intervention/Treatment: The study tests subcutaneous injections of Tildrakizumab 100 mg, an experimental drug, administered on Day 1, Week 4, and every 12 weeks thereafter. It is compared against a placebo to determine its efficacy in treating genital psoriasis.

Study Design: This is an interventional study with a randomized, parallel assignment. It employs a double-blind approach, meaning both participants and outcomes assessors are unaware of the treatment allocations. The primary purpose is treatment-focused, aiming to provide relief for patients with genital psoriasis.

Study Timeline: The study began on March 21, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on July 22, 2025, indicating ongoing recruitment and progress.

Market Implications: This study could significantly impact Sun Pharmaceutical’s stock performance and investor sentiment, as successful results may lead to a new treatment option in the dermatology market. Competitors in the psoriasis treatment space will be closely monitoring these developments, as a successful outcome could shift market dynamics.

The study is currently ongoing, with further details available on the ClinicalTrials portal.